| VLDL Receptor | |
|---|---|
| Gene Symbol | [VLDLR](/genes/vldlr) |
| UniProt | P98155 |
| PDB | 7D73 |
| Molecular Weight | 105 kDa |
| Localization | Cell membrane, Postsynaptic density |
| Family | LDLR family |
| Ligands | Reelin, Apolipoprotein E |
| Brain Expression | Cortex, Hippocampus, Cerebellum |
The VLDL Receptor (VLDLR) is a 105 kDa cell surface receptor belonging to the low-density lipoprotein receptor (LDLR) family. It is encoded by the VLDLR gene and plays crucial roles in the developing and adult nervous system. VLDLR binds Reelin, a large extracellular matrix protein essential for neuronal migration, synaptic plasticity, and memory formation. In the adult brain, VLDLR continues to mediate Reelin signaling at synapses, where it regulates NMDA receptor trafficking, dendritic spine morphology, and long-term potentiation.
VLDLR is expressed throughout the brain with particularly high levels in the hippocampus, cerebral cortex, and cerebellum. Dysregulation of VLDLR-mediated signaling has been implicated in Alzheimer's Disease, cerebellar ataxia, and various neurodevelopmental disorders.
The receptor belongs to the LDLR superfamily, which includes multiple related receptors involved in lipid metabolism and cell signaling. Unlike other LDLR family members that primarily function in peripheral tissue lipid uptake, VLDLR has evolved specialized functions in the central nervous system, where it mediates the extracellular signaling of Reelin—a critical guidance molecule for neuronal development and synaptic function.
VLDLR emerged as a specialized receptor during vertebrate evolution, with orthologs present in all jawed vertebrates. The receptor's extracellular domain contains multiple copies of LDLR class A (LA) repeats, which were likely acquired through gene duplication events. This domain architecture allows for high-affinity binding to Reelin while maintaining the endocytic properties characteristic of the LDLR family.
In mammals, VLDLR is highly conserved, with >90% amino acid identity between mouse and human orthologs. This conservation underscores the receptor's essential function in brain development and function. Knockout mouse studies have revealed that VLDLR is dispensable for embryonic survival but critical for postnatal brain development and cognitive function.
VLDLR is a type I transmembrane receptor with the following structural features:
The extracellular domain of VLDLR (~792 amino acids) contains multiple functional modules:
LDLR class A (LA) repeats (7 copies): These ~40-residue motifs contain conserved cysteine residues and form the ligand-binding region. Each LA repeat can bind one molecule of Reelin, with the full extracellular domain capable of binding multiple Reelin molecules. The affinity of individual LA repeats for Reelin varies, with the first two repeats contributing most significantly to high-affinity binding.
Epidermal growth factor (EGF) repeats (3 copies): These ~40-residue repeats are interspersed between the LA repeats and the β-propeller domain. The EGF repeats are involved in receptor recycling by facilitating the release of ligand in acidic endosomes.
β-propeller domain: This unique structure within the LDLR family serves as a pH-dependent "gate" that regulates ligand release. At neutral pH (extracellular environment), the β-propeller is open and allows ligand binding. At acidic pH (endosomal lumen), the β-propeller closes, displacing the ligand for degradation or recycling.
O-linked sugar domain: Located between the EGF repeats and the transmembrane domain, this region contains multiple threonine and serine residues that undergo O-linked glycosylation. The O-linked sugars contribute to proper folding and stability of the receptor.
VLDLR binds two primary ligands with distinct physiological roles:
Reelin: A large extracellular glycoprotein (~400 kDa) produced primarily by Cajal-Retzius cells in the developing brain and by interneurons in the adult brain. Reelin binds to VLDLR with high affinity (Kd ~1-10 nM) and triggers downstream signaling cascades essential for neuronal migration, synaptic plasticity, and cognitive function.
Apolipoprotein E: A lipid transport protein that plays important roles in CNS lipid homeostasis. Importantly, the ApoE4 isoform—a major genetic risk factor for AD—competes with Reelin for VLDLR binding. This competition may contribute to synaptic dysfunction in ApoE4 carriers.
The crystal structure of the VLDLR extracellular domain (PDB: 7D73) has revealed:
During brain development, VLDLR plays an essential role in neuronal migration, the process by which neurons travel from their birthplace to their final position in the developing brain:
Cortical layer formation: Reelin-VLDLR signaling regulates the inside-out layering of cortical neurons. During corticogenesis, newly born neurons migrate radially from the ventricular zone to form the six-layered cortex. The first-born neurons occupy the deepest layer (layer VI), while later-born neurons migrate past existing neurons to form more superficial layers. This "inside-out" pattern depends on Reelin signaling through VLDLR. When VLDLR is absent, neurons fail to migrate past their destined layers, resulting in cortical malformation characterized by inverted cortical layering.
Cerebellar development: VLDLR is critical for proper cerebellar layering and granule cell migration. Granule cells born in the external germinal layer migrate inward to form the internal granule cell layer. This migration requires Reelin-VLDLR signaling, and VLDLR deficiency results in abnormal cerebellar architecture.
Hippocampal formation: Reelin-VLDLR signaling guides hippocampal neuronal positioning. The dentate gyrus granule cells and CA1 pyramidal neurons require proper Reelin signaling for correct layering.
Olfactory bulb development: VLDLR participates in the migration of interneurons in the olfactory bulb.
The mechanism of Reelin-VLDLR-mediated neuronal migration involves:
In the adult brain, VLDLR continues to play important synaptic roles beyond its developmental function in neuronal migration:
NMDA receptor trafficking: VLDLR signaling regulates the postsynaptic accumulation of NMDA receptors, affecting synaptic plasticity. Reelin-VLDLR signaling promotes the insertion of NMDA receptors into the postsynaptic density, enhancing excitatory synaptic transmission.
Dendritic spine morphology: Reelin-VLDLR signaling maintains dendritic spine shape and density. VLDLR knockouts show reduced spine density and abnormal spine morphology, which correlates with cognitive deficits.
Long-term potentiation (LTP): VLDLR is required for proper LTP in the hippocampus. Mice lacking VLDLR show deficits in spatial memory that are associated with impaired LTP. Reelin enhances LTP through VLDLR-mediated mechanisms.
Synaptic scaling: VLDLR participates in homeostatic synaptic scaling responses, where neurons adjust the strength of all synapses in response to chronic activity changes.
GABAergic synapse development: VLDLR regulates the development and function of GABAergic inhibitory synapses, affecting the balance between excitation and inhibition.
Upon Reelin binding, VLDLR triggers a complex intracellular cascade:
Reelin → VLDLR/ApoER2 → DAB1 phosphorylation → Src family kinases
↓
PI3K/Akt → GSK-3β inhibition → Microtubule stabilization
↓
Crk/CrkL → Rap1 → NMDA receptor trafficking
↓
Limk1 → Cofilin → Actin dynamics
This pathway regulates:
VLDLR also plays roles in:
VLDLR has been increasingly implicated in AD pathogenesis through multiple mechanisms:
Synaptic dysfunction: Reduced Reelin and VLDLR expression in AD brain may contribute to synaptic loss. Reelin-VLDLR signaling is essential for maintaining synaptic spines, and its loss correlates with cognitive decline. Postmortem studies have shown decreased VLDLR expression in the hippocampus of AD patients.
Aβ interactions: Amyloid-beta binds to VLDLR and may interfere with Reelin signaling. The ApoE4 isoform, a major AD risk factor, competes with Reelin for VLDLR binding, potentially disrupting normal Reelin function in ApoE4 carriers.
Tau phosphorylation: VLDLR signaling modulates GSK-3β activity, which affects tau phosphorylation. Dysregulated VLDLR signaling may contribute to tau pathology through increased GSK-3β activity.
Memory deficits: VLDLR knockout mice show memory deficits similar to early AD, supporting a role in cognitive function. These deficits include impaired spatial memory in the Morris water maze and reduced LTP.
Genetic associations: VLDLR polymorphisms have been associated with AD risk in some populations. Several GWAS studies have identified VLDLR variants that may modify AD risk, though results have been inconsistent across cohorts.
Neuroinflammation: VLDLR signaling may modulate neuroinflammation through effects on microglial function and cytokine production.
Aging: VLDLR expression decreases with age, which may contribute to age-related cognitive decline. This decrease may compound other AD-related pathologies.
VLDLR mutations cause cerebellar ataxia through disrupted Reelin signaling:
Homozygous VLDLR mutations: Cause dysequilibrium syndrome, characterized by:
Heterozygous mutations: Cause milder ataxic symptoms, often with cognitive features
The mechanism involves disrupted Reelin signaling leading to abnormal cerebellar layering and connectivity. Patients with VLDLR mutations show characteristic neuroimaging findings including cerebellar vermis hypoplasia and cortical atrophy.
VLDLR is implicated in several neurodevelopmental conditions:
VLDLR represents a therapeutic target for multiple neurological conditions:
Reelin mimetics: Small molecules that activate VLDLR could enhance synaptic function in AD. These could bypass the need for full-length Reelin while maintaining beneficial signaling.
VLDLR agonists: Therapeutic proteins mimicking Reelin function. Engineered Reelin fragments or VLDLR-binding peptides could be developed.
ApoE4 antagonists: Blocking ApoE4 competition with Reelin for VLDLR binding could restore normal signaling in ApoE4 carriers.
GSK-3β inhibitors: Already in development for AD, these compounds act downstream of VLDLR signaling.
Gene therapy: Viral vector-mediated delivery of VLDLR or Reelin could restore signaling in deficient states.
| Partner | Interaction Type | Functional Significance |
|---|---|---|
| Reelin | Primary extracellular ligand | Neuronal migration, synaptic plasticity |
| ApoER2 | Coreceptor | Enhanced signaling, receptor crosstalk |
| DAB1 | Adapter protein | Primary signaling partner, recruits downstream effectors |
| Src family kinases | Phosphorylation | DAB1 phosphorylation, downstream activation |
| PSD-95 | PDZ interaction | Synaptic scaffolding, NMDAR organization |
| NMDA receptors | Modulation | Synaptic plasticity regulation |
| Apolipoprotein E | Competition | Lipid transport, AD risk factor |
| Disabled-2 (Dab2) | Endocytosis | Receptor internalization |
| ARH | Endocytosis | Clathrin adapter for endocytosis |
| PI3K | Signaling | Akt activation, cell survival |
| Crk/CrkL | Signaling | Rap1 activation, cytoskeletal regulation |
Herz & Chen (2008): Comprehensive review of Reelin-VLDLR-ApoER2 signaling in synaptic function and disease.
Teleshkin et al. (2018): Demonstrated VLDLR-mediated Reelin signaling in hippocampal neuronal development and memory.
Mukherjee et al. (2019): Showed ApoE4 competition with Reelin for VLDLR binding as a mechanism of AD risk.
Ishii et al. (2016): Documented VLDLR dysregulation in AD brains.
Sato et al. (2015): Characterized VLDLR mutations causing cerebellar ataxia.
The VLDL Receptor (VLDLR) is a critical signaling receptor in the developing and adult nervous system. Through its interaction with Reelin, VLDLR regulates neuronal migration during development and synaptic plasticity in the adult brain. VLDLR dysfunction contributes to multiple neurological conditions, including Alzheimer's disease, cerebellar ataxia, and neurodevelopmental disorders.
The receptor's structure, with multiple LDLR class A repeats and a pH-dependent β-propeller, enables high-affinity Reelin binding and regulated signaling. Downstream pathways including DAB1, PI3K/Akt, and Crk/CrkL mediate the diverse effects of VLDLR signaling on cytoskeletal dynamics, synaptic function, and neuronal survival.
Therapeutic targeting of VLDLR offers potential for treating Alzheimer's disease and other conditions, though challenges remain in delivering therapeutics to the CNS and achieving appropriate receptor activation.